Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT-EHA CAR-T 2019 | The future landscape of CAR T-cell therapy

Elaine Vickers • 20 Mar 2019
EBMT-EHA CAR-T 2019
Acute Lymphoblastic Leukemia General Leukemia Lymphoma CAR-T

In this video, Elaine Vickers, PhD, of Science Communicated Ltd., Manchester, UK, discusses the future of immunotherapy with CAR T-cells. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Dr Vickers mentions the most anticipated upcoming strategies that may improve the performance of CAR T-cell therapy in treating cancer. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).

More from Elaine Vickers

The importance of nursing education in CAR-T therapy
0:59
The importance of nursing education in CAR-T therapy
Elaine Vickers • 10 Feb 2023
Exciting updates in the CAR-T space from an educator's perspective
1:33
Exciting updates in the CAR-T space from an educator's perspective
Elaine Vickers • 10 Feb 2023
CAR-T Meeting 2020 highlights: CAR T-cell design, molecular biology & solid tumors
1:16
CAR-T Meeting 2020 highlights: CAR T-cell design, molecular biology & solid tumors
Elaine Vickers • 30 Jan 2020
Importance of educating nurses on CAR T-cell therapy
2:21
Importance of educating nurses on CAR T-cell therapy
Elaine Vickers • 30 Jan 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals